Highly multiplexed detection and quantification of 18 biologically relevant KMT2A rearrangements using single-molecule counting

AML with KMT2A rearrangements (KMT2A-r) is an aggressive subtype marked by poor prognosis, chemotherapy resistance, and high relapse rates, and while more than 90 fusion partners have been identified, most cases involve a small number of recurrent partners. The recent approval of menin inhibitors has intensified research interest in KMT2A-r AML, increasing the need for sensitive, quantitative tools to study fusion transcript expression, treatment response, and disease progression. Conventional dPCR is limited in multiplexing capacity, and NGS adds workflow complexity, turnaround time, and cost, creating challenges for studies involving multiple fusion transcripts and large sample sets. This poster presents a rapid, highly multiplexed approach on Countable PCR for simultaneously detecting and quantifying the most prevalent KMT2A fusion transcripts to advance KMT2A-r AML research and the evaluation of emerging targeted therapies.